Market closedNon-fractional
Adverum Biotechnologies/ADVM
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Adverum Biotechnologies
Adverum Biotechnologies, Inc. is a clinical-stage gene therapy company. The Company discovers and develops gene therapy product candidates that provides durable efficacy by inducing sustained expression of a therapeutic protein. Its lead product candidate, ixoberogene soroparvovec (Ixo-vec), is a single, in-office intravitreal (IVT) injection gene therapy product designed to deliver long-term durable levels of aflibercept associated with a sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with frequent anti-vascular endothelial growth factor (VEGF) IVT injections. Ixo-vec is being developed for the treatment of patients with wet age-related macular degeneration. Its second product candidate, ADVM-062 (AAV.7m8-L-opsin), is a gene therapy product candidate being developed to treat patients suffering from blue cone monochromacy (BCM) via a single IVT injection. It also developing an early-stage pipeline of gene therapy programs.
Ticker
ADVM
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology & Drugs
Headquarters
Redwood city, United States
Employees
121
Website
adverum.com
ADVM Metrics
BasicAdvanced
$164M
Market cap
-
P/E ratio
-$10.23
EPS
1.13
Beta
-
Dividend rate
Price and volume
Market cap
$164M
Beta
1.13
52-week high
$29.70
52-week low
$7.24
Average daily volume
6.7
Financial strength
Current ratio
9.241
Management effectiveness
Return on assets (TTM)
-41.55%
Return on equity (TTM)
-66.40%
Return on investment (TTM)
-47.50%
Valuation
Price to book
0.902
Price to tangible book (TTM)
0.902
Growth
Revenue change (TTM)
-100.00%
Earnings per share change (TTM)
30.06%
What the Analysts think about ADVM
Analyst Ratings
Majority rating from 7 analysts.
ADVM Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
NaN%
Net income
-$25M
4.22%
Profit margin
0.00%
NaN%
ADVM Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$3.10
-$3.30
-$2.30
-$1.50
-
Expected
-$3.29
-$3.15
-$3.37
-$1.40
-$1.52
Surprise
-5.72%
4.71%
-31.68%
6.79%
-
ADVM News
AllArticlesVideos
Adverum Biotechnologies Reports First Quarter 2024 Financial Results and Provides Pipeline Highlights
GlobeNewsWire·2 months ago
Adverum Biotechnologies to Participate in Upcoming May Investor Conferences
GlobeNewsWire·2 months ago
Adverum Biotechnologies to Present LUNA 26-week Phase 2 Interim Analysis at the ASRS Annual Scientific Meeting
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Adverum Biotechnologies stock?
Adverum Biotechnologies (ADVM) has a market cap of $164M as of July 06, 2024.
What is the P/E ratio for Adverum Biotechnologies stock?
The price to earnings (P/E) ratio for Adverum Biotechnologies (ADVM) stock is 0 as of July 06, 2024.
Does Adverum Biotechnologies stock pay dividends?
No, Adverum Biotechnologies (ADVM) stock does not pay dividends to its shareholders as of July 06, 2024.
When is the next Adverum Biotechnologies dividend payment date?
Adverum Biotechnologies (ADVM) stock does not pay dividends to its shareholders.
What is the beta indicator for Adverum Biotechnologies?
Adverum Biotechnologies (ADVM) has a beta rating of 1.13. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.
Buy or sell Adverum Biotechnologies stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.